ClinicalTrials.gg
TerminatedNCT04536350Updated Jan 18, 2024

Inhaled Aviptadil for the Treatment of COVID-19 in Patients at High Risk for ARDS

A Phase 2 interventional study of Aviptadil 67μg and Placebo 0.9% NaCl solution in Covid19, Corona Virus Infection and ARDS, sponsored by Prof. Dr. Jörg Leuppi. Terminated at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-18.

Sponsored by Prof. Dr. Jörg Leuppi · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Difficulties recruiting participants for the Aviptadil study as there are nowadays very few hospitalized COVID patients. Continuous screening has been carried out but none of the patients met the eligibility criteria for the study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
83
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 97 studies in COVID-19 with a site in Switzerland — 6 open to participants now, 10 under way, 1 of them phase 3. COVID-19 · Switzerland.

Enrollment
27th of 49
83 · median 100
Started
2021
with 24 others
Phase 2
8 of 97
1 open now
Registered
42nd of 97
by date
Lead sponsor
2 of 97
Prof. Dr. Jörg Leuppi

Among the 97 studies in COVID-19 with a site in Switzerland, this one is the 27th largest by enrollment of the 49 interventional ones that give a count, is one of 25 that started in 2021, is one of 8 in phase 2, and was the 42nd registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

6 of the 97 studies in COVID-19 with a site in Switzerland are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 97 studies in COVID-19 with a site in Switzerland, or all of them as a file.
02

Study summary

The world is currently experiencing a coronavirus (CoV-2) pandemic. A new (SARS)-CoV infection epidemic began in Wuhan, Hubei, China, in late 2019; originally called 2019- nCoV the virus is now known as SARSCoV- 2 and the disease it causes COVID-19. Previous CoV epidemics included severe acute respiratory syndrome (SARS)-CoV, which started in China in 2003 and Middle East respiratory syndrome (MERS)-CoV in the Middle East, which started in 2012. The mortality rates were >10% for SARS and >35% for MERS. The direct cause of death is generally due to ensuing severe atypical pneumonia and ensuing acute respiratory distress syndrome (ARDS). Pneumonia also is generally the cause of death for people who develop influenza, although the mortality rate is lower (1%-3% for the influenza A H5N1 pandemic of 1918-1919 in the United States). Risk factors for a poor outcome of SARS-CoV-2 infection have so far been found to include older age and co-morbidities including chronic cardiovascular and respiratory conditions and current smoking status. In May 2020, the FDA authorized the emergency use of remdesivir for treatment of COVID-19 disease based on topline date of two clinical trials, even though an underpowered clinical trial did not find significant improvement in COVID- 19 patients treated with remdesivir. Nevertheless, remdesivir is the first and so far, only approved treatment for COVID-19. Additionally further trials and clinical observations have not found a significant benefit of other antiviral drugs. Although the results of several studies are still pending, there is still a desperate need for an effective, safe treatment for COVID-19. Aviptadil, which is a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP), might be beneficial in patients at risk of developing ARDS. Nonclinical studies demonstrate that VIP is highly concentrated in the lung, where it reduces inflammation.

Read the detailed description

About 20% of individuals with Corona Virus disease (COVID-19) experience more severe disease characterized by significant respiratory symptoms including acute respiratory distress syndrome (ARDS). ARDS is a known lethal complication due to its low blood oxygenation levels and may result in organ failure. Until now, there are no specific vaccines or therapeutic drugs targeting SARS-CoV-2, alternative therapeutic interventions are needed to prevent and ameliorate respiratory conditions associated with COVID-19 to effectively reduce mortality and prevent ICU admissions. Aviptadil, which is a synthetic form of Human Vasoactive Intestinal Polypeptide (VIP), might be beneficial in patients at risk of developing ARDS. Nonclinical studies demonstrate that VIP is highly concentrated in the lung, where it prevents N-methyl-D-aspartate (NMDA)-induced caspase-3 activation, inhibits IL-6 and TNFa production and protects against HCl-induced pulmonary edema. Further, in animal model systems of lung injury in mice, rats, guinea pigs, sheep, swine and dogs, Aviptadil was shown to restore barrier function at the endothelial/alveolar interface and to protect the lung and other organs from failure. In Europe, Aviptadil is approved for human use and has been shown to be safe in phase II trials for sarcoidosis, pulmonary fibrosis, bronchospasm, erectile dysfunction as well as in a phase I trial in ARDS in the past two decades. In the US, VIP has been given FDA Orphan Drug Designation for the treatment of ARDS and was admitted to the FDA Corona Virus Technology Accelerator Program. In a phase I trial of Aviptadil performed by Sami Said in the early 2000s, eight patients with severe ARDS on mechanical ventilation were treated with ascending doses of intravenous VIP. Seven patients (88%) were successfully extubated and were alive at the five day time point. Six (75%) left the hospital and one (13%) died of an unrelated cardiac event. A phase II clinical trial using intravenous Aviptadil in patients with COVID-19 infection and ARDS has begun. Further, a phase II/III clinical trial will study the effect of inhaled Aviptadil for the treatment of non-acute lung injury in COVID- 19 and begins in June 2020. In Europe, two phase II trials of Aviptadil have been conducted. Further, studies with healthy volunteers have shown that inhaled Aviptadil is well tolerated with few adverse effects.

03

Conditions studied

  • Covid19
  • Corona Virus Infection
  • ARDS
  • Aviptadil

Keywords

  • Covid 19
  • Corona Virus Infection
  • acute respiratory distress syndrome (ARDS)
  • Aviptadil
  • Faster recovery
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • COVID-19 infection diagnosed
  • Risk factors for the development of an ARDS according to an adapted EALI (early acute lung injury score) ≥ 2 Points (with at least one point from the EALI score)

EALI Score:

  • 2-6l O2 supplementation to achieve a SaO2>90%: 1 point
  • >6l O2 supplementation to achieve a SaO2>90%: 2 points
  • Respiratory rate ≥ 30/min: 1 point
  • : 1 Point

Modification (for adapting for risk factors for ARDS in SARS-CoV-2 affected patients

  • Arterial hypertension: 1 point
  • Diabetes: 1 point
  • Fever > 39°C: 1 point

    • Age > 18 years
    • Ability to adequate compliance with the inhalation manoeuvre
    • Ability to sign the

Exclusion criteria

Exclusion Criteria:

  • Known or highly suspected bacterial infection (antibiotic treatment to avoid bacterial superinfection may be allowed)
  • PCT ≥ 1μg/l
  • Mechanical ventilation
  • Inability to conduct inhalation therapy
  • Hemodynamic instability with requirement of vasopressor therapy
  • Severe comorbidities interfering with the safe participation at the trial according to the treating physician
  • Pregnancy
  • Systemic
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
83 participants (actual)

Study arms

  • Experimental
    Aviptadil Treatment

    Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.

    Drug: Aviptadil 67μg

  • Placebo comparator
    Placebo Treatment

    Participants in the control group will receive an Inhalation of 0.9% NaCl solution three times a day for 10 days

    Drug: Placebo 0.9% NaCl solution

Interventions

  • DrugAviptadilStudies of AviptadilAviptadil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive standard care plus a dose of 67μg nebulized Aviptadil three times a day for ten days.

  • DrugPlacebo 0.9% NaCl solution

    Patiens will receive Standard care plus 0.9% NaCl solution three times a day for ten days

06

What researchers measure

Primary outcomes

  1. Time to clinical improvement

    Time to clinical improvement of a decrease of at least two points on a seven-point ordinal scale of clinical status or discharged alive from hospital. The seven-point scale consists of the following categories: 1. not hospitalized; 2. hospitalized, not requiring supplemental oxygen; 3. hospitalized, requiring supplemental oxygen; 4. hospitalized, requiring nasal high-flow oxygen therapy, non-invasive mechanical ventilation, or both; 5. hospitalized, intubation and mechanical ventilation; 6. ventilation and additional organ support - pressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO); 7. death

    Time frame: Randomization until discharge from hospital but up to maximum 28 days

Secondary outcomes

  1. Frequency of mechanical ventilation

    Frequency of Patient who need mechanical ventilation during hospital stay

    Time frame: Randomization until discharge from hospital up to maximum 28 days

  2. Oxygen supplementation

    Time requiring oxygen supplementation

    Time frame: Randomization until discharge from hospital up to maximum 28 days

  3. SaO2

    Slope in SaO2

    Time frame: Randomization until discharge from hospital up to maximum 28 days

  4. FiO2

    Slope in FiO2

    Time frame: Randomization until discharge from hospital but up to maximum 28 days

  5. C-reactive Protein

    Slope in C-reactive Protein

    Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days

  6. Neutrophile

    Neutrophile ratio

    Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days

  7. lymphocyte

    lymphocyte ratio

    Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days

  8. Interleukine 6

    Interleukine 6 level

    Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days

  9. Procalcitonin

    Procalcitonin level

    Time frame: measured at baseline, at least every 7 days and at discharge up to maximum 28 days

  10. Frequency of Multi organ dysfunction Syndrome (MODS)

    Frequency of Patient who showed a multi organ dysfunction Syndrome during Hospital stay

    Time frame: Randomization until discharge from hospital up to maximum 28 days

Other outcomes

  1. Hospitalization

    duration of hospitalization in survivors

    Time frame: randomization till discharge of hospital up to 28 days

  2. treatment initiation to death

    Time from treatment initiation to death

    Time frame: Treatment initiation to death up to maximum 28 days

  3. Blood pressure

    Blood pressure will be assessed daily in mmHg

    Time frame: Daily until discharge up to maximum 28 days

  4. Heart rate

    Heart rate will be assessed daily in bpm

    Time frame: Daily until discharge up to maximum 28 days

  5. Respiratory rate

    Respiratory rate will be assessed daily in Counts per minute

    Time frame: Daily until discharge up to maximum 28 days

  6. Body temperature (auricular) in °C

    Body temperature (auricular) will be assessed daily in °C

    Time frame: Daily until discharge up to maximum 28 days

  7. Pulse oximetry

    Pulse oximetry will be assessed daily in %

    Time frame: Daily until discharge up to maximum 28 days

  8. Glasgow Coma Scale

    Glasgow Coma Scale will be assessed daily The lowes possible score is 3 = deep coma or death The highest possible score is 15 = Fully awake

    Time frame: Daily until discharge up to maximum 28 days

  9. Dispnea and caugh

    Visual analogue scale for dyspnea and cough as patient-related outcome parameter

    Time frame: Randomization until discharge from hospital up to maximum 28 days

07

Study locations

2 sites
  • Cantonal Hospital Baselland Liestal
    Liestal, BL 4410, Switzerland
  • Cantonal Hospital St.Gallen
    St.Gallen, 9007, Switzerland
08

References and documents

Publications

  • Boesing M, Abig K, Brandle M, Brutsche M, Burri E, Frye BC, Giezendanner S, Grutters JC, Haas P, Heisler J, Jaun F, Leuppi-Taegtmeyer AB, Luthi-Corridori G, Muller-Quernheim J, Nuesch R, Pohl W, Rassouli F, Leuppi JD. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. Trials. 2022 Sep 20;23(1):790. doi: 10.1186/s13063-022-06723-w. PubMed 36127739 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2021 to primary completion in Jun 2023, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2020
First posted
Sep 2, 2020
StartActual
May 18, 2021
Primary completionActual
Jun 14, 2023
CompletionActual
Jun 14, 2023
Last update
Jan 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04536350
Lead sponsor
Prof. Dr. Jörg Leuppi
Responsible party
Prof. Dr. Jörg Leuppi (Professor of Internal Medicine, Cantonal Hosptal, Baselland) — Sponsor-investigator
First posted
Sep 2, 2020
Start date
May 18, 2021
Primary completion
Jun 14, 2023
Completion
Jun 14, 2023
Last update
Jan 18, 2024

Study contacts

Jörg D Leuppi, Professor
principal investigator · Cantonal Hosptal, Baselland

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aviptadil

Start the discussion